Initial expectations for genome-wide association studies were high, as such studies
promised to rapidly transform personalized medicine with individualized disease risk …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified
more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data …

Purpose Germline mutations in DNA damage repair (DDR) genes are identified in a
significant proportion of patients with metastatic prostate cancer, but the clinical implications …

Genome-wide association studies (GWAS) have identified 76 variants associated with
prostate cancer risk predominantly in populations of European ancestry. To identify …

Context Although the widespread use of prostate-specific antigen (PSA) has led to an early
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …

Background Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53)
cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome …

Despite chemotherapy and novel androgen‐receptor signalling inhibitors (ARSi) have been
approved during the last decades, metastatic castration‐resistant prostate cancer (mCRPC) …

Long noncoding RNAs (lncRNAs) represent an attractive class of candidates to mediate
cancer risk. Through integrative analysis of the lncRNA transcriptome with genomic data and …

Context For more precise, personalized care in prostate cancer (PC), a new classification
based on molecular features relevant for prognostication and treatment stratification is …